HC Wainwright Reiterates Buy Rating for Sensus Healthcare (NASDAQ:SRTS)

HC Wainwright reiterated their buy rating on shares of Sensus Healthcare (NASDAQ:SRTS) in a research report released on Friday,Benzinga reports. They currently have a $12.00 target price on the stock.

Separately, Lake Street Capital decreased their price objective on Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th.

Sensus Healthcare Price Performance

Shares of Sensus Healthcare stock opened at $4.46 on Friday. Sensus Healthcare has a 1 year low of $3.09 and a 1 year high of $9.33. The stock has a market cap of $73.57 million, a price-to-earnings ratio of 11.15 and a beta of 1.11. The firm’s 50-day moving average is $5.42 and its two-hundred day moving average is $6.51.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. On average, equities analysts expect that Sensus Healthcare will post 0.32 earnings per share for the current year.

Institutional Investors Weigh In On Sensus Healthcare

Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. purchased a new stake in shares of Sensus Healthcare during the 4th quarter valued at $27,000. Barclays PLC acquired a new position in Sensus Healthcare during the 4th quarter valued at about $35,000. BNP Paribas Financial Markets purchased a new stake in Sensus Healthcare in the fourth quarter valued at about $47,000. IFP Advisors Inc acquired a new stake in Sensus Healthcare in the fourth quarter worth about $95,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of Sensus Healthcare during the fourth quarter worth about $109,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.